Enliven Therapeutics, Inc. financial data

Symbol
ELVN on Nasdaq
Location
Boulder, CO
Fiscal year end
31 December
Latest financial report
10-K - Q4 2025 - 03 Mar 2026

Key Ratios

Label TTM Value / Value Unit Change %
Current Ratio 2893% % 82%
Debt-to-equity 3.6% % -46%
Return On Equity -24% % 17%
Return On Assets -23% % 15%

Shares

Label TTM Value / Value Unit Change %
Entity Common Stock, Shares Outstanding 59,800,406 shares 22%
Common Stock, Shares, Outstanding 59,440,045 shares 21%
Entity Public Float $836,000,000 USD 22%
Common Stock, Value, Issued $59,000 USD 20%
Weighted Average Number of Shares Outstanding, Basic 56,664,226 shares 20%
Weighted Average Number of Shares Outstanding, Diluted 56,664,226 shares 20%

Income Statement

Label TTM Value / Value Unit Change %
Research and Development Expense $85,856,000 USD 6.3%
General and Administrative Expense $33,802,000 USD 42%
Operating Income (Loss) $119,658,000 USD -14%
Nonoperating Income (Expense) $15,964,000 USD 2.8%
Income Tax Expense (Benefit) $0 USD
Net Income (Loss) Attributable to Parent $103,694,000 USD -16%
Earnings Per Share, Basic -1.83 USD/shares 3.2%
Earnings Per Share, Diluted -1.83 USD/shares 3.2%

Balance Sheet

Label TTM Value / Value Unit Change %
Cash and Cash Equivalents, at Carrying Value $98,896,000 USD -20%
Marketable Securities, Current $363,725,000 USD 92%
Cash, Cash Equivalents, and Short-term Investments $462,600,000 USD 48%
Assets, Current $474,878,000 USD 49%
Property, Plant and Equipment, Net $34,000 USD -93%
Operating Lease, Right-of-Use Asset $383,000 USD
Other Assets, Noncurrent $656,000 USD -91%
Assets $476,168,000 USD 46%
Accounts Payable, Current $2,159,000 USD 61%
Liabilities, Current $16,568,000 USD 4.1%
Operating Lease, Liability, Noncurrent $0 USD
Other Liabilities, Noncurrent $103,000 USD
Liabilities $16,568,000 USD 4.1%
Accumulated Other Comprehensive Income (Loss), Net of Tax $334,000 USD 507%
Retained Earnings (Accumulated Deficit) $347,166,000 USD -43%
Stockholders' Equity Attributable to Parent $459,600,000 USD 48%
Liabilities and Equity $476,168,000 USD 46%

Popular Metrics

Label TTM Value / Value Unit Change %
Net Cash Provided by (Used in) Operating Activities $24,127,000 USD -3.3%
Net Cash Provided by (Used in) Financing Activities $234,000 USD -100%
Net Cash Provided by (Used in) Investing Activities $1,427,000 USD
Common Stock, Shares Authorized 100,000,000 shares 0%
Common Stock, Shares, Issued 59,440,045 shares 21%
Common Stock, Par or Stated Value Per Share 0.001 USD/shares 0%
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents $98,896,000 USD -20%
Deferred Tax Assets, Valuation Allowance $92,278,000 USD 45%
Deferred Tax Assets, Gross $92,386,000 USD 45%
Operating Lease, Liability $399,000 USD -43%
Depreciation $74,000 USD -6.3%
Comprehensive Income (Loss), Net of Tax, Attributable to Parent $103,415,000 USD -16%
Lessee, Operating Lease, Liability, to be Paid $414,000 USD
Property, Plant and Equipment, Gross $263,000 USD -81%
Operating Lease, Liability, Current $399,000 USD
Lessee, Operating Lease, Liability, to be Paid, Year One $414,000 USD
Lessee, Operating Lease, Liability, Undiscounted Excess Amount $15,000 USD
Deferred Tax Assets, Operating Loss Carryforwards $43,251,000 USD 76%
Preferred Stock, Shares Issued 0 shares
Preferred Stock, Shares Authorized 10,000,000 shares 0%
Unrecognized Tax Benefits $34,469,000 USD 3%
Operating Lease, Payments $400,000 USD 33%
Additional Paid in Capital $806,373,000 USD 46%
Preferred Stock, Shares Outstanding 0 shares
Depreciation, Depletion and Amortization $300,000 USD 0%
Share-based Payment Arrangement, Expense $34,019,000 USD 69%
Preferred Stock, Par or Stated Value Per Share 0.001 USD/shares 0%